Sign In

Login

Password

Forgot Password ? Sign Up

Ipilimumab (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ipilimumab" in Polish language version.

refsWebsite
Global rank Polish rank
6nih.gov
4th place
7th place
6clinicaltrials.gov
5,225th place
3,508th place
5doi.org
2nd place
6th place
1berkeley.edu
580th place
1,186th place
1rp.pl
1,774th place
24th place
1asco.org
low place
low place
1independent.co.uk
36th place
134th place

asco.org

berkeley.edu

crl.berkeley.edu

clinicaltrials.gov

doi.org

  • J. Yuan, S. Gnjatic, H. Li, S. Powel i inni. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.. „Proc Natl Acad Sci U S A”. 105 (51), s. 20410-5, Dec 2008. DOI: 10.1073/pnas.0810114105. PMID: 19074257. 
  • JD. Wolchok, B. Neyns, G. Linette, S. Negrier i inni. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.. „Lancet Oncol”. 11 (2), s. 155-64, Feb 2010. DOI: 10.1016/S1470-2045(09)70334-1. PMID: 20004617. 
  • FS. Hodi, SJ. O'Day, DF. McDermott, RW. Weber i inni. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.. „N Engl J Med”. 363 (8), s. 711-23, Jun 2010. DOI: 10.1056/NEJMoa1003466. PMID: 20525992. PMCID: PMC3549297. 
  • NE. Schartz, C. Farges, I. Madelaine, H. Bruzzoni i inni. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.. „Melanoma Res”. 20 (3), s. 247-50, Jun 2010. DOI: 10.1097/CMR.0b013e3283364a37. PMID: 20216240. 
  • SJ. O'Day, M. Maio, V. Chiarion-Sileni, TF. Gajewski i inni. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.. „Ann Oncol”, Feb 2010. DOI: 10.1093/annonc/mdq013. PMID: 20147741. 

independent.co.uk

nih.gov

ncbi.nlm.nih.gov

  • MA. Morse. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.. „Curr Opin Mol Ther”. 7 (6), s. 588-97, Dec 2005. PMID: 16370382. 
  • J. Yuan, S. Gnjatic, H. Li, S. Powel i inni. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.. „Proc Natl Acad Sci U S A”. 105 (51), s. 20410-5, Dec 2008. DOI: 10.1073/pnas.0810114105. PMID: 19074257. 
  • JD. Wolchok, B. Neyns, G. Linette, S. Negrier i inni. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.. „Lancet Oncol”. 11 (2), s. 155-64, Feb 2010. DOI: 10.1016/S1470-2045(09)70334-1. PMID: 20004617. 
  • FS. Hodi, SJ. O'Day, DF. McDermott, RW. Weber i inni. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.. „N Engl J Med”. 363 (8), s. 711-23, Jun 2010. DOI: 10.1056/NEJMoa1003466. PMID: 20525992. PMCID: PMC3549297. 
  • NE. Schartz, C. Farges, I. Madelaine, H. Bruzzoni i inni. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.. „Melanoma Res”. 20 (3), s. 247-50, Jun 2010. DOI: 10.1097/CMR.0b013e3283364a37. PMID: 20216240. 
  • SJ. O'Day, M. Maio, V. Chiarion-Sileni, TF. Gajewski i inni. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.. „Ann Oncol”, Feb 2010. DOI: 10.1093/annonc/mdq013. PMID: 20147741. 

rp.pl